The weight loss drug market, driven by GLP-1 therapies, is expected to grow to $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors targeted exposure to this expanding sector, including major pharmaceutical companies like Novo Nordisk and Eli Lilly, as well as biotech and healthcare service firms. Innovations are broadening beyond current leaders to include oral drugs, genetic treatments, and muscle-preserving therapies, signaling diverse growth opportunities. THNR tracks the VettaFi Weight Loss Drug & Treatment Index and focuses on the entire clinical and digital ecosystem supporting obesity treatment.
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...
Novo, a Danish pharmaceutical company, saw its shares fall up to 7% after announcing plans to launch over five new drugs with blockbuster potential by 2030 and targeting pipeline sales exceeding $23 billion by 2035. The company aims to grow revenue f...
Anthropic has revealed it operates a wet biology lab where its AI models conduct physical experiments, aiming to bridge AI theories with real-world biology. This lab functions like a typical biotech facility, supporting both in-house research and col...
